2010 Fiscal Year Final Research Report
The treatment strategy for GVHD by infusion of PUVA-treated dendritic cells
Project/Area Number |
21790973
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Pediatrics
|
Research Institution | 国立病院機構金沢医療センター (2010) Department of Clinical Research, National Hospital Organization Kanazawa Medical Center (2009) |
Principal Investigator |
前馬 秀昭 国立病院機構金沢医療センター, 臨床研究部, 小児科医師 (10419335)
|
Project Period (FY) |
2009 – 2010
|
Keywords | GVHD / 制御性樹状細胞 / 造血幹細胞移植 / PUVA療法 |
Research Abstract |
Bone marrow-derived cultured DCs acquired tolerogenicity by PUVA (psoralen+UVA) treatment in mice. In MLR assays, strong tolerogenicity was observed when adding PUVA-DCs generated from the same strain of stimulator cells, or responder cells, or even from third party strain into MLR mixture. That is, the PUVA-treated DCs have tolerogenic function in a MHC-independent manner, in part, due to the reduced expression levels of CD80 and CD86. To clarify the mechanisms of how PUVA-treated DCs induce tolerogenicity in further detail, we performed MLR with the addition of neutralizing antibodies against IL-10 or TGF-b1 or both. Neutralization of immunosuppressive cytokines had no effects on MLR. We then showed that cell-to-cell contact between PUVA-DCs and alloreactive T-cells was needed to mediate the regulatory effect by transwell experiment. Next we compared the expression of the indoleamine 2,3-dioxygenase (IDO), which induces T-cell anergy by tryptophan depletion and by the production of metabolic byproducts collectively known as kynurenines, by real-time PCR between PUVA-DCs and BM-DCs. An increase IDO gene transcription level was observed in PUVA-DCs about 5 times more than in BM-DCs (p<0.01). In conclusion, PUVA-DCs acquired regulatory function in a MHC-independent manner by upregulation of IDO. Infusion of PUVA-treated DCs could have a great potential to treat lethal acute GVHD in clinical settings.
|
Research Products
(5 results)